BRAF and melanoma: This approval was derived from the results of the CheckMate-037 study, which showed that nivolumab had better objective response rates than the investigator's choice chemotherapy in patients with metastatic or unresectable melanoma whose cancers had advanced after being treated with ipilimumab, a ± BRAF inhibitor [53].